Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,775 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Labinaz M, Kilaru R, Pieper K, Marso SP, Kitt MM, Simoons ML, Califf RM, Topol EJ, Armstrong PW, Harrington RA. Labinaz M, et al. Among authors: harrington ra. Circulation. 2002 Jan 22;105(3):322-7. doi: 10.1161/hc0302.102578. Circulation. 2002. PMID: 11804987 Clinical Trial.
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.
Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA. Mahaffey KW, et al. Among authors: harrington ra. Am Heart J. 2002 Feb;143(2):242-8. doi: 10.1067/mhj.2002.120145. Am Heart J. 2002. PMID: 11835026
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial.
Giugliano RP, Roe MT, Harrington RA, Gibson CM, Zeymer U, Van de Werf F, Baran KW, Hobbach HP, Woodlief LH, Hannan KL, Greenberg S, Miller J, Kitt MM, Strony J, McCabe CH, Braunwald E, Califf RM; INTEGRITI Investigators. Giugliano RP, et al. J Am Coll Cardiol. 2003 Apr 16;41(8):1251-60. doi: 10.1016/s0735-1097(03)00123-2. J Am Coll Cardiol. 2003. PMID: 12706917 Free article. Clinical Trial.
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators; Bates E, Bode C, Costa M, Gibson CM, Granger C, Green C, Grimes K, Harrington R, Huber K, Kleiman N, Mochly-Rosen D, Roe M, Sadowski Z, Solomon S, Widimsky P. Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators, et al. Among authors: harrington r. Circulation. 2008 Feb 19;117(7):886-96. doi: 10.1161/CIRCULATIONAHA.107.759167. Epub 2008 Feb 4. Circulation. 2008. PMID: 18250271 Clinical Trial.
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. James S, et al. Among authors: harrington r. Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003. Am Heart J. 2009. PMID: 19332184 Clinical Trial.
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
White H, Held C, Stewart R, Watson D, Harrington R, Budaj A, Steg PG, Cannon CP, Krug-Gourley S, Wittes J, Trivedi T, Tarka E, Wallentin L. White H, et al. Among authors: harrington r. Am Heart J. 2010 Oct;160(4):655-61. doi: 10.1016/j.ahj.2010.07.006. Am Heart J. 2010. PMID: 20934559 Clinical Trial.
Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).
Kunadian V, Giugliano RP, Newby LK, Zorkun C, Guo J, Bagai A, Montalescot G, Braunwald E, Califf RM, Van de Werf F, Armstrong PW, Harrington R, Gibson CM. Kunadian V, et al. Among authors: harrington r. Am J Cardiol. 2014 Apr 15;113(8):1297-305. doi: 10.1016/j.amjcard.2014.01.404. Epub 2014 Jan 31. Am J Cardiol. 2014. PMID: 24607027 Clinical Trial.
D-Dimer elevation and adverse outcomes.
Halaby R, Popma CJ, Cohen A, Chi G, Zacarkim MR, Romero G, Goldhaber SZ, Hull R, Hernandez A, Mentz R, Harrington R, Lip G, Peacock F, Welker J, Martin-Loeches I, Daaboul Y, Korjian S, Gibson CM. Halaby R, et al. Among authors: harrington r. J Thromb Thrombolysis. 2015 Jan;39(1):55-9. doi: 10.1007/s11239-014-1101-6. J Thromb Thrombolysis. 2015. PMID: 25006010 Free PMC article. Review.
1,775 results